Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study.

被引：0
|
作者：
Shamash, J.
Jacob, J.
Powles, T.
Agrawal, S.
Mutsvangwa, K.
Saunders, N.
Wilson, P.
Stebbing, J.
机构：
[1] St Bartholomews Hosp, London, England
[2] Univ London Imperial Coll Sci Technol & Med, London, England
[3] St Barthlomews Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2573
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC).
    Morris, Michael J.
    Bruce, Justine Yang
    Reyno, Leonard M.
    Anand, Banmeet
    Hartford, Alan
    Jelaca-Maxwell, Kathy
    Lackey, Jacqueline
    Eisenberger, Mario A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [12] A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Rathkopf, Dana E.
    Shore, Neal
    Antonarakis, Emmanuel S.
    Berry, William R.
    Alumkal, Joshi J.
    Tutrone, Ronald
    Saleh, Mansoor N.
    Redfern, Charles H.
    Hauke, Ralph J.
    Liu, Glenn
    Steinbrecher, Jill Elise
    Danila, Daniel Costin
    Curley, Tracy
    Arauz, Gabrielle
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [13] Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel
    Duran, Ignacio
    Montagut, Clara
    Calvo, Emiliano
    Galtes, Susana
    Navarrete, Alicia
    Rodriguez-Pascual, Jesus
    Hidalgo, Manuel
    Francisco Rodriguez-Moreno, Juan
    Cubillo, Antonio
    Garcia, Antonia
    Sanchez, Lorena
    Barbas, Coral
    Viqueira, Andrea
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [14] A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC)
    Bilusic, M.
    Gulley, J. L.
    Heery, C.
    Apolo, A. B.
    Arlen, P. M.
    Rauckhorst, M.
    McMahon, S.
    Dahut, W. L.
    Schlom, J.
    Madan, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [15] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Hideyuki Akaza
    Hirotsugu Uemura
    Taiji Tsukamoto
    Seiichiro Ozono
    Osamu Ogawa
    Hideki Sakai
    Mototsugu Oya
    Mikio Namiki
    Satoshi Fukasawa
    Akito Yamaguchi
    Hiroji Uemura
    Yasuo Ohashi
    Hideki Maeda
    Atsushi Saito
    Kentaro Takeda
    Seiji Naito
    International Journal of Clinical Oncology, 2016, 21 : 773 - 782
  • [16] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Akaza, Hideyuki
    Uemura, Hirotsugu
    Tsukamoto, Taiji
    Ozono, Seiichiro
    Ogawa, Osamu
    Sakai, Hideki
    Oya, Mototsugu
    Namiki, Mikio
    Fukasawa, Satoshi
    Yamaguchi, Akito
    Uemura, Hiroji
    Ohashi, Yasuo
    Maeda, Hideki
    Saito, Atsushi
    Takeda, Kentaro
    Naito, Seiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (04) : 773 - 782
  • [17] Validation of a whole-blood RNA prognostic signature in metastatic castration-resistant prostate cancer (mCRPC) patients
    Oh, William K.
    Venkata, Uma Chippada
    Wang, Li
    Reese, Emma
    Yee, Tiffany
    Kochukoshy, Teena
    Tsao, Che-Kai
    Galsky, Matt D.
    Zhu, Jun
    Gong, Yixuan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [18] A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
    Ross, Robert W.
    Galsky, Matthew D.
    Scher, Howard I.
    Magidson, Jay
    Wassmann, Karl
    Lee, Gwo-Shu Mary
    Katz, Leah
    Subudhi, Sumit K.
    Anand, Aseem
    Fleisher, Martin
    Kantoff, Philip W.
    Oh, William K.
    LANCET ONCOLOGY, 2012, 13 (11): : 1105 - 1113
  • [19] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Barata, Pedro C.
    Cooney, Matthew
    Mendiratta, Prateek
    Tyler, Allison
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1085 - 1092
  • [20] Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)
    De Jager, R. L.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H.
    Earhart, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345